Vir Biotechnology, Inc. (VIR)

63.08 -1.03 (-1.61%) As of 12:01PM EST. Market open.

Vir Biotechnology, Inc.

499 Illinois Street
Suite 500
San Francisco, CA 94158
United States
415 906 4324
http://www.vir.bio

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 297

Key executives

Name	Title	Pay	Exercised	Year born
Dr. George A. Scangos	Pres, CEO & Director	785.83k	N/A	1948
Dr. Klaus Frueh	Co-Founder & Scientific Advisor	177.66k	N/A	1960
Mr. Howard Horn	CFO & Sec.	599.25k	N/A	1977
Dr. Herbert W. Virgin IV	Exec. VP of Research & Chief Scientific Officer	949.9k	N/A	1956
Dr. Jay Parrish	Co-Founder & Chief Bus. Officer	N/A	N/A	1975
Dr. Lawrence Corey	Co-Founder & Scientific Advisor	N/A	N/A	N/A
Dr. Louis J. Picker	Co-Founder & Scientific Advisor	N/A	N/A	N/A
Dr. Michael E. Kamarck	Chief Technology Officer	N/A	N/A	1951
Mr. Steven J. Rice	Chief Admin. Officer	N/A	N/A	N/A
Dr. Neera Dahiya Ravindran M.D., MBA	VP and Head of Investor Relations & Strategic Communications	N/A	N/A	N/A

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.

Corporate governance

Vir Biotechnology, Inc.’s ISS governance QualityScore as of 2 December 2020 is 8. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 9; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.